Amendment #1213 to H5500

CHIA & HPC Assessments

Mr. Reid of Lynn moves to amend the bill, by adding the following new sections:

"Section XX. Section 6 of chapter 6D, as most recently amended by section 5 of chapter 342 of the acts of 2024, is hereby amended by striking the section (d) in its entirety and replacing with the following: “(d)  To the maximum extent permissible under federal law, and provided that such assessment will not result in any reduction of federal financial participation in Medicaid, the assessed amount for pharmaceutical manufacturing companies shall be not less than 5 per cent nor more than 10 per cent of the amount appropriated by the general court for the expenses of the commission minus amounts collected from: (i) filing fees; (ii) fees and charges generated by the commission; and (iii) federal matching revenues received for these expenses or received retroactively for expenses of predecessor agencies. Each pharmaceutical manufacturing company shall pay such assessed amount multiplied by the ratio of spending for the manufacturer’s prescription drugs in the commonwealth compared to total spending for prescription drugs in the commonwealth.”

Section XY.  Section 7 of chapter 12C, as most recently amended by section 21 of chapter 342 of the acts of 2024, is hereby amended by striking the section (d) in its entirety and replacing with the following: “(d) To the maximum extent permissible under federal law, and provided that such assessment will not result in any reduction of federal financial participation in Medicaid, the assessed amount for pharmaceutical manufacturing companies shall be not less than 5 per cent nor more than 10 per cent of the amount appropriated by the general court for the expenses of the center minus amounts collected from: (i) filing fees; (ii) fees and charges generated by the center’s publication or dissemination of reports and information; and (iii) federal matching revenues received for these expenses or received retroactively for expenses of predecessor agencies.  Each pharmaceutical manufacturing company shall pay such assessed amount multiplied by the ratio of spending for the manufacturer’s prescription drugs in the commonwealth compared to total spending for prescription drugs in the commonwealth.”